Sandoz Group AG Registered Shares SDZ
News
Generic weight-loss drugs? They're coming - eventually, executive says
Sandoz reports second-quarter sales and half-year 2024 results
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation
Sandoz Receives FDA Approval for Wyost, Jubbonti
Novartis Net Profit Boosted by Gain From Sandoz Spinoff — Update
Novartis Net Profit Boosted by Gain From Sandoz Spinoff